Allergan, an AbbVie Company, to Present Data from its Leading Portfolio of Eye Care Treatments at the 2022 American Glaucoma Society Annual Meeting Pharmaceutical Investing
Second Phase 3 Induction Study Confirms Upadacitinib Improved Clinical and Endoscopic Outcomes in Patients with Crohn's Disease Pharmaceutical Investing
AbbVie Announces Provincial Reimbursement for VENCLEXTA® with Obinutuzumab for Patients with Previously Untreated Chronic Lymphocytic Leukemia in Alberta, Saskatchewan, British Columbia, and Manitoba Pharmaceutical Investing
Potent Ventures Appoints Mr. Bruce Gillies, Former PepsiCo Executive, to Its Advisory Board in Preparation for Launch of The Gummy Project Resource Investing
BriaCell Appoints Leading Immunologist Dr. Alexander Kharazi to its Scientific Advisory Board Company News
AbbVie Submits Supplemental New Drug Application to U.S. FDA for cariprazine for the Adjunctive Treatment of Major Depressive Disorder Pharmaceutical Investing
Bristol Myers Squibb Presents Interim Results from Long-Term Study Reinforcing Maintenance of Response and Safety Profile of Zeposia in Patients with Moderately to Severely Active Ulcerative Colitis Pharmaceutical Investing
Potent Ventures Appoints Seasoned Chief Marketing Officer in Preparation for Launch of the Gummy Project Resource Investing
